Drugs / Damoctocog
Damoctocog
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03364998 | Nov 2017 → Jan 2018 | hemophilia A | Bayer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Damoctocog | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03364998 ↗ |
| Known as | BAY94-9027 | “BAY 94-9027 is an extended-half-life, recombinant factor VIII (rFVIII) product conjugated with a 60-kDa branched polyethylene glycol (PEG) molecule indicated for use in...” PMID 31236667 ↗ Jun 20191“Damoctocog (Jivi, BAY94-9027)” NCT03364998 ↗ |
| Known as | Jivi | “Damoctocog (Jivi, BAY94-9027)” NCT03364998 ↗ |
| Modality | Protein / enzyme biologic | “BAY 94-9027 is an extended-half-life, recombinant factor VIII (rFVIII) product” PMID 31236667 ↗ Jun 2019 |
| Route | Intravenous | “after intravenous administration” NCT03364998 ↗ |